Biom X Inc. PHGE
We take great care to ensure that the data presented and summarized in this overview for BiomX Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PHGE
View all-
Deerfield Management Company, L.P. (Series C) New York, NY6.11MShares$2.02 Million0.06% of portfolio
-
Orbimed Advisors LLC San Diego, CA4.52MShares$1.49 Million0.05% of portfolio
-
Johnson & Johnson New Brunswick, NJ1.92MShares$634,6560.18% of portfolio
-
8 Vc Gp I, LLC Austin, TX1.09MShares$358,4430.62% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny80.6KShares$26,5980.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny19.8KShares$6,5210.0% of portfolio
-
Jump Financial, LLC Chicago, IL19.2KShares$6,3380.0% of portfolio
-
Xtx Topco LTD London, X010.2KShares$3,3620.0% of portfolio
-
Pnc Financial Services Group, Inc. Pittsburgh, PA4KShares$1,3200.0% of portfolio
-
Bank Of America Corp Charlotte, NC1Shares$00.0% of portfolio
Latest Institutional Activity in PHGE
Top Purchases
Top Sells
About PHGE
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Insider Transactions at PHGE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 15
2024
|
Orbi Med Israel Bio Fund Gp Limited Partnership > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
24,344
-0.18%
|
$0
$0.38 P/Share
|
May 15
2024
|
Orbi Med Israel Bio Fund Gp Limited Partnership > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
9,280,408
+40.21%
|
$0
$0.24 P/Share
|
May 15
2024
|
Fibrosis Foundation Cystic |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
4,778,265
+33.87%
|
-
|
Mar 15
2024
|
James E Flynn Director |
BUY
Grant, award, or other acquisition
|
Indirect |
6,110,098
+50.0%
|
-
|
Nov 29
2023
|
Assaf Oron Chief Business Officer |
SELL
Open market or private sale
|
Direct |
10,914
-70.76%
|
$0
$0.36 P/Share
|
May 22
2023
|
Assaf Oron Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
3,192
+22.63%
|
$0
$0.27 P/Share
|
May 19
2023
|
Assaf Oron Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
6,521
+45.78%
|
$0
$0.28 P/Share
|
May 18
2023
|
Assaf Oron Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
1,201
+50.0%
|
$0
$0.27 P/Share
|
Feb 27
2023
|
Orbi Med Israel Bio Fund Gp Limited Partnership > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
348,000
+9.92%
|
$0
$0.24 P/Share
|
Nov 04
2022
|
Chidozie Ugwumba |
SELL
Open market or private sale
|
Indirect |
1,501
-0.05%
|
$0
$0.38 P/Share
|
Nov 03
2022
|
Chidozie Ugwumba |
SELL
Open market or private sale
|
Indirect |
2,000
-0.07%
|
$0
$0.37 P/Share
|
Nov 02
2022
|
Chidozie Ugwumba |
SELL
Open market or private sale
|
Indirect |
2,416
-0.08%
|
$0
$0.36 P/Share
|
Nov 01
2022
|
Chidozie Ugwumba |
SELL
Open market or private sale
|
Indirect |
1,300
-0.04%
|
$0
$0.36 P/Share
|
Oct 31
2022
|
Chidozie Ugwumba |
SELL
Open market or private sale
|
Indirect |
3,300
-0.11%
|
$0
$0.37 P/Share
|
Oct 28
2022
|
Chidozie Ugwumba |
SELL
Open market or private sale
|
Indirect |
1,526
-0.05%
|
$0
$0.36 P/Share
|
Oct 27
2022
|
Chidozie Ugwumba |
SELL
Open market or private sale
|
Indirect |
1,505
-0.05%
|
$0
$0.36 P/Share
|
Oct 26
2022
|
Chidozie Ugwumba |
SELL
Open market or private sale
|
Indirect |
12,500
-0.41%
|
$0
$0.35 P/Share
|
Oct 25
2022
|
Chidozie Ugwumba |
SELL
Open market or private sale
|
Indirect |
3,072
-0.1%
|
$0
$0.36 P/Share
|
Oct 24
2022
|
Chidozie Ugwumba |
SELL
Open market or private sale
|
Indirect |
5,900
-0.19%
|
$0
$0.35 P/Share
|
Oct 21
2022
|
Chidozie Ugwumba |
SELL
Open market or private sale
|
Indirect |
5,400
-0.18%
|
$0
$0.37 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 6.11M shares |
---|---|
Exercise of in-the-money or at-the-money derivatives securities | 14.1M shares |
Open market or private sale | 35.3K shares |
---|